Novel nucleoside phosphoramidates as inhibitors of HIV: Studies on the stereochemical requirements of the phosphoramidate amino acid

24Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Novel phosphoramidate derivatives of the anti-HIV nucleoside analogue d4T were designed to act as labile membrane-soluble prodrugs of the bio-active free nucleotide d4TMP. We herein reveal the very marked dependence of the antiviral activity of these phosphoramidates upon the stereochemistry of the amino acid attached to the phosphate centre; with a strong preference for the L-stereochemistry. These phosphate triesters were shown to liberate amino acid derivatives of the nucleotide intracellularly. These novel analogues, typified by alaninyl d4T monophosphate, may act as intracellular sources of the free nucleotides. The alaninyl d4T adducts themselves exert an antiviral effect when administered extracellularly, but again with clear distinctions between the L- and D-series. This evidence indicates that extracellularly administered blocked triesters derived from L-amino acids can generate d4TMP intracellularly, by a new pathway which is highly dependent on the amino acid stereochemistry.

Cite

CITATION STYLE

APA

McGuigan, C., Salgado, A., Yarnold, C., Harries, T. Y., De Clercq, E., & Balzarini, J. (1996). Novel nucleoside phosphoramidates as inhibitors of HIV: Studies on the stereochemical requirements of the phosphoramidate amino acid. Antiviral Chemistry and Chemotherapy, 7(4), 184–188. https://doi.org/10.1177/095632029600700402

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free